Rare Disease Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient ...
Researchers advanced the therapy with an AI platform that uses machine learning models trained on patient endotyping, multiomics, biomarker, and clinical data. The US Food and Drug Administration (FDA ...
No ICANS or deaths occurred, and all serious adverse events resolved without sequelae. Cizutamig, a T-cell engager, is generally safe and well tolerated in generalized myasthenia gravis (MG) and other ...
All 24 participants in the phase 1b trial maintained their baseline motor milestones, and half achieved at least 1 new WHO motor milestone after salanersen treatment. The US Food and Drug ...
The mixed vascular-fibrotic group demonstrated the shortest median progression-free survival (36 months) and the highest independent risk of disease progression. Researchers proposed a new ...
Three‐dimensional imaging revealed a loss of normal microvascular architecture, areas of hyper- and hypovascularization, and microvascular obstruction due to capillary thrombosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results